KPV

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). The mechanistic story that drives current interest is not melanocortin-receptor signaling but transporter-mediated cellular uptake: KPV enters intestinal epithelial cells and immune cells through PepT1, an oligopeptide transporter whose expression rises during intestinal inflammation. Once intracellular, the tripeptide inhibits NF-κB and MAP kinase signaling at nanomolar concentrations and suppresses pro-inflammatory cytokine secretion ([Dalmasso et al., *Gastroenterology* 2008, 134:166–178](https://doi.org/10.1053/j.gastro.2007.10.026)). Critically, the anti-inflammatory effect persists in mice with non-functional MC1R, indicating it is not melanocortin-receptor-mediated — KPV essentially acts as a small-molecule cytokine-pathway modulator that gets concentrated where it's needed because the relevant transporter is upregulated at the inflammation site.

KPV is the most mechanistically clean inflammatory-bowel-disease peptide candidate on this site, and the one with the largest gap between the rodent literature and the human evidence base. Across DSS- and TNBS-induced colitis models in mice, oral KPV reduced disease severity, lowered pro-inflammatory cytokine levels, decreased neutrophil infiltration (myeloperoxidase activity dropped roughly 50% in some published cohorts), and improved epithelial integrity. The transporter-targeting design has also been explored in nanoparticle-delivery work, where hyaluronic-acid-functionalized particles concentrate KPV further at the colonic mucosa for ulcerative colitis models. The clinical translation is essentially absent. There is no published large randomized human trial of oral KPV for IBD, ulcerative colitis, or any other inflammatory indication. The practitioner and self-experimenter community has expanded around KPV for gut symptoms, post-antibiotic recovery, and skin inflammation, but the supporting human evidence is anecdote-tier. This is a peptide where the mechanistic case is genuinely strong and the human RCT evidence is genuinely thin — both can be true at once, and the page should be read accordingly. The orally bioavailable design is part of why the peptide attracts attention: most peptides on this site require subcutaneous injection, and KPV is one of the few with a credible mechanistic argument for oral activity in a specific tissue compartment (the gut). That same property — transporter-targeted absorption in inflamed mucosa — is also what makes the rodent-to-human translation so consequential and so unfinished.